Investment
Features
FeesSafety
Academy
More
Pluang+

Compare VanEck Uranium & Nuclear ETF (NLR) vs TransMedics Group Inc (TMDX) Price & Performance

VanEck Uranium & Nuclear ETFTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

VanEck Uranium & Nuclear ETF vs TransMedics Group Inc — how do they compare? VanEck Uranium & Nuclear ETF trades at $122.98, while TransMedics Group Inc trades at $85.89 (market cap $3.06B). Which is the better fit depends on your goals.

NLRTMDX
Sector
Sector/ThematicTechnology
52-Week High
$164.37$150.42
52-Week Low
$102.70$61.99
Market Cap
$3.06B
Enterprise Value
$3.46B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

VanEck Uranium & Nuclear ETF

No Aura AI signal available yet.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.

The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About VanEck Uranium & Nuclear ETF

VanEck Uranium and Nuclear ETF seeks exposure to companies involved in uranium mining and the nuclear power industry. Its holdings may include miners, utilities, reactor-related companies, and nuclear equipment or service providers.

Read more on NLR

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX